Role of NRP1 in Bladder Cancer Pathogenesis and Progression
PDF (12M)
+12 authors
Journal: 2021/July - Frontiers in Oncology
Abstract:
Bladder urothelial carcinoma (BC) is a fatal invasive malignancy and the most common malignancy of the urinary system. In the current study, we investigated the function and mechanisms of Neuropilin-1 (NRP1), the co-receptor for vascular endothelial growth factor, in BC pathogenesis and progression. The expression of NRP1 was evaluated using data extracted from GEO and HPA databases and examined in BC cell lines. The effect on proliferation, apoptosis, angiogenesis, migration, and invasion of BC cells were validated after NRP1 knockdown. After identifying differentially expressed genes (DEGs) induced by NRP1 silencing, GO/KEGG and IPA® bioinformatics analyses were performed and specific predicted pathways and targets were confirmed in vitro. Additionally, the co-expressed genes and ceRNA network were predicted using data downloaded from CCLE and TCGA databases, respectively. High expression of NRP1 was observed in BC tissues and cells. NRP1 knockdown promoted apoptosis and suppressed proliferation, angiogenesis, migration, and invasion of BC cells. Additionally, after NRP1 silencing the activity of MAPK signaling and molecular mechanisms of cancer pathways were predicted by KEGG and IPA® pathway analysis and validated using western blot in BC cells. NRP1 knockdown also affected various biological functions, including antiviral response, immune response, cell cycle, proliferation and migration of cells, and neovascularisation. Furthermore, the main upstream molecule of the DEGs induced by NRP1 knockdown may be NUPR1, and NRP1 was also the downstream target of NUPR1 and essential for regulation of FOXP3 expression to activate neovascularisation. DCBLD2 was positively regulated by NRP1, and PPAR signaling was significantly associated with low NRP1 expression. We also found that NRP1 was a predicted target of miR-204, miR-143, miR-145, and miR-195 in BC development. Our data provide evidence for the biological function and molecular aetiology of NRP1 in BC and for the first time demonstrated an association between NRP1 and NUPR1, FOXP3, and DCBLD2. Specifically, downregulation of NRP1 contributes to BC progression, which is associated with activation of MAPK signaling and molecular mechanisms involved in cancer pathways. Therefore, NRP1 may serve as a target for new therapeutic strategies to treat BC and other cancers.
Keywords: NRP1; apoptosis; bladder cancer; invasion; migration; neovascularisation; proliferation.
Open in
PUBMED | DOI | Google Scholar | Wikipedia
Relations:
Content
Citations
(1)
References
(56)
Diseases
(3)
Chemicals
(1)
Processes
(2)
Anatomy
(3)
Similar articles
Articles by the same authors
Discussion board

Role of NRP1 in Bladder Cancer Pathogenesis and Progression

+8 authors
Click here for additional data file.(1.6M, pdf)
Click here for additional data file.(1.6M, pdf)
Click here for additional data file.(24M, pdf)
Click here for additional data file.(202K, xlsx)
Click here for additional data file.(75K, xlsx)
Click here for additional data file.(14K, xlsx)
Click here for additional data file.(39K, xlsx)
Click here for additional data file.(713K, docx)
Click here for additional data file.(25K, xlsx)
Click here for additional data file.(33K, xlsx)
Click here for additional data file.(17K, xlsx)
Click here for additional data file.(15K, xlsx)
Click here for additional data file.(52K, xlsx)
Click here for additional data file.(11K, xlsx)
Click here for additional data file.(14K, xlsx)
Department of Urology, Xuzhou Central Hospital, Xuzhou, China,
Medical College of Soochow University, Suzhou, China,
College of Life Sciences, Jiangsu Normal University, Xuzhou, China,
Department of Central Laboratory, Xuzhou Central Hospital, Xuzhou, China,
Nanjing University of Traditional Chinese Medicine, Nanjing, China,
Edited by: Bianca Nitzsche, Charité – Universitätsmedizin Berlin, Germany
Reviewed by: Pasquale Ditonno, University of Bari, Italy; Mariana Chantre Justino, Rio de Janeiro State University, Brazil
*Correspondence: Cong-hui Han, nc.ude.ubtb.ts@rotcodhcnah; Lin Hao, moc.361@uohzuxniloah
†These authors have contributed equally to this work and share first authorship
This article was submitted to Genitourinary Oncology, a section of the journal Frontiers in Oncology
Edited by: Bianca Nitzsche, Charité – Universitätsmedizin Berlin, Germany
Reviewed by: Pasquale Ditonno, University of Bari, Italy; Mariana Chantre Justino, Rio de Janeiro State University, Brazil
Received 2021 Mar 26; Accepted 2021 Jun 7.
Copyright © 2021 Dong, Ma, Shi, Zhang, Zhou, Li, Zhang, Pang, Li, Zhang, Fan, Zhu, Xue, Li, Liu, Hao and Han
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Abstract

Bladder urothelial carcinoma (BC) is a fatal invasive malignancy and the most common malignancy of the urinary system. In the current study, we investigated the function and mechanisms of Neuropilin-1 (NRP1), the co-receptor for vascular endothelial growth factor, in BC pathogenesis and progression. The expression of NRP1 was evaluated using data extracted from GEO and HPA databases and examined in BC cell lines. The effect on proliferation, apoptosis, angiogenesis, migration, and invasion of BC cells were validated after NRP1 knockdown. After identifying differentially expressed genes (DEGs) induced by NRP1 silencing, GO/KEGG and IPA bioinformatics analyses were performed and specific predicted pathways and targets were confirmed in vitro. Additionally, the co-expressed genes and ceRNA network were predicted using data downloaded from CCLE and TCGA databases, respectively. High expression of NRP1 was observed in BC tissues and cells. NRP1 knockdown promoted apoptosis and suppressed proliferation, angiogenesis, migration, and invasion of BC cells. Additionally, after NRP1 silencing the activity of MAPK signaling and molecular mechanisms of cancer pathways were predicted by KEGG and IPA pathway analysis and validated using western blot in BC cells. NRP1 knockdown also affected various biological functions, including antiviral response, immune response, cell cycle, proliferation and migration of cells, and neovascularisation. Furthermore, the main upstream molecule of the DEGs induced by NRP1 knockdown may be NUPR1, and NRP1 was also the downstream target of NUPR1 and essential for regulation of FOXP3 expression to activate neovascularisation. DCBLD2 was positively regulated by NRP1, and PPAR signaling was significantly associated with low NRP1 expression. We also found that NRP1 was a predicted target of miR-204, miR-143, miR-145, and miR-195 in BC development. Our data provide evidence for the biological function and molecular aetiology of NRP1 in BC and for the first time demonstrated an association between NRP1 and NUPR1, FOXP3, and DCBLD2. Specifically, downregulation of NRP1 contributes to BC progression, which is associated with activation of MAPK signaling and molecular mechanisms involved in cancer pathways. Therefore, NRP1 may serve as a target for new therapeutic strategies to treat BC and other cancers.

Keywords: NRP1, bladder cancer, proliferation, apoptosis, neovascularisation, migration, invasion
Abstract

Acknowledgments

We appreciate the public database provider and maintenance staffs.

Acknowledgments
Click here for additional data file.(1.6M, pdf)Click here for additional data file.(1.6M, pdf)Click here for additional data file.(24M, pdf)Click here for additional data file.(202K, xlsx)Click here for additional data file.(75K, xlsx)Click here for additional data file.(14K, xlsx)Click here for additional data file.(39K, xlsx)Click here for additional data file.(713K, docx)Click here for additional data file.(25K, xlsx)Click here for additional data file.(33K, xlsx)Click here for additional data file.(17K, xlsx)Click here for additional data file.(15K, xlsx)Click here for additional data file.(52K, xlsx)Click here for additional data file.(11K, xlsx)Click here for additional data file.(14K, xlsx)

References

  • 1. Siegel RL, Miller K D, Jemal A. Cancer Statistics, 2019. CA Cancer J Clin (2019) 69(1):7–34. 10.3322/caac.21551 [] [[PubMed]
  • 2. Feng RM, Zong YN, Cao S M, Xu RH. Current Cancer Situation in China: Good or Bad News From the 2018 Global Cancer Statistics? Cancer Commun (Lond) (2019) 39(1):22. 10.1186/s40880-019-0368-6 ] [
  • 3. Smaldone MC, Jacobs BL, Smaldone A M, Hrebinko RL, Jr. Long-Term Results of Selective Partial Cystectomy for Invasive Urothelial Bladder Carcinoma. Urology (2008) 72(3):613–6. 10.1016/j.urology.2008.04.052 [] [[PubMed]
  • 4. Vashistha V, Quinn DI, Dorff T B, Daneshmand S. Current and Recent Clinical Trials for Perioperative Systemic Therapy for Muscle Invasive Bladder Cancer: A Systematic Review. BMC Cancer (2014) 14:966–80. 10.1186/1471-2407-14-966 ] [
  • 5. Jubb AM, Strickland LA, Liu SD, Mak J, Schmidt M, Koeppen H. Neuropilin-1 Expression in Cancer and Development. J Pathol (2012) 226(1):50–60. 10.1002/path.2989 [] [[PubMed]
  • 6. Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, et al. . A Requirement for Neuropilin-1 in Embryonic Vessel Formation. Development (1999) 126(21):4895–902. 10.1242/dev.126.21.4895 [] [[PubMed]
  • 7. Cheng W, Fu D, Wei ZF, Xu F, Xu XF, Liu YH, et al. . NRP-1 Expression in Bladder Cancer and its Implications for Tumor Progression. Tumour Biol (2014) 35(6):6089–94. 10.1007/s13277-014-1806-3 [] [[PubMed]
  • 8. Pang K, Zhang Z, Hao L, Shi Z, Chen B, Zang G, et al. . The ERH Gene Regulates Migration and Invasion in 5637 and T24 Bladder Cancer Cells. BMC Cancer (2019) 19(1):225. 10.1186/s12885-019-5423-9 ] [
  • 9. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, et al. . Gene Expression in the Urinary Bladder: A Common Carcinoma in Situ Gene Expression Signature Exists Disregarding Histopathological Classification. Cancer Res (2004) 64(11):4040–8. 10.1158/0008-5472.CAN-03-3620 [] [[PubMed]
  • 10. Borisov N, Tkachev V, Suntsova M, Kovalchuk O, Zhavoronkov A, Muchnik I, et al. . A Method of Gene Expression Data Transfer From Cell Lines to Cancer Patients for Machine-Learning Prediction of Drug Efficiency. Cell Cycle (2018) 17(4):486–91. 10.1080/15384101.2017.1417706 ] [
  • 11. Song BN, Kim SK, Mun JY, Choi YD, Leem S H, Chu IS. Identification of an Immunotherapy-Responsive Molecular Subtype of Bladder Cancer. EBioMedicine (2019) 50:238–45. 10.1016/j.ebiom.2019.10.058 ] [
  • 12. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI Gene Expression and Hybridization Array Data Repository. Nucleic Acids Res (2002) 30(1):207–10. 10.1093/nar/30.1.207 ] [
  • 13. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. . Proteomics. Tissue-Based Map of the Human Proteome. Science (2015) 347(6220):1260419. 10.1126/science.1260419 [] [[PubMed]
  • 14. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. . The Cancer Cell Line Encyclopedia Enables Predictive Modelling of Anticancer Drug Sensitivity. Nature (2012) 483(7391):603–7. 10.1038/nature11003 ] [
  • 15. The Gene Ontology C. Expansion of the Gene Ontology Knowledgebase and Resources. Nucleic Acids Res (2017) 45(D1):D331–D8. 10.1093/nar/gkw1108 ] [
  • 16. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: New Perspectives on Genomes, Pathways, Diseases and Drugs. Nucleic Acids Res (2017) 45(D1):D353–D61. 10.1093/nar/gkw1092. Kanehisa M,Goto S. KEGG kyoto encyclopedia of genes and genomes. Nucleic Acids Res (2000) 28(1)27-30. 10.1093/nar/28.1.27. ] [
  • 17. Yu G, Wang LG, Yan G R, He QY. DOSE: An R/Bioconductor Package for Disease Ontology Semantic and Enrichment Analysis. Bioinformatics (2015) 31(4):608–9. 10.1093/bioinformatics/btu684 [] [[PubMed]
  • 18. Yu G, Wang LG, Han Y, He QY. Clusterprofiler: An R Package for Comparing Biological Themes Among Gene Clusters. OMICS (2012) 16(5):284–7. 10.1089/omi.2011.0118 ] [
  • 19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. . Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles. Proc Natl Acad Sci U S A (2005) 102(43):15545–50. 10.1073/pnas.0506580102 ] [
  • 20. Appleton BA, Wu P, Maloney J, Yin J, Liang WC, Stawicki S, et al. . Structural Studies of Neuropilin/Antibody Complexes Provide Insights Into Semaphorin and VEGF Binding. EMBO J (2007) 26(23):4902–12. 10.1038/sj.emboj.7601906 ] [
  • 21. Chen H, Bagri A, Zupicich JA, Zou Y, Stoeckli E, Pleasure SJ, et al. . Neuropilin-2 Regulates the Development of Selective Cranial and Sensory Nerves and Hippocampal Mossy Fiber Projections. Neuron (2000) 25(1):43–56. 10.1016/S0896-6273(00)80870-3 [] [[PubMed]
  • 22. Lin J, Zhang Y, Wu J, Li L, Chen N, Ni P, et al. . Neuropilin 1 (NRP1) Is a Novel Tumor Marker in Hepatocellular Carcinoma. Clin Chim Acta (2018) 485:158–65. 10.1016/j.cca.2018.06.046 [] [[PubMed]
  • 23. Yacoub M, Coulon A, Celhay O, Irani J, Cussenot O, Fromont G. Differential Expression of the Semaphorin 3A Pathway in Prostatic Cancer. Histopathology (2009) 55(4):392–8. 10.1111/j.1365-2559.2009.03406.x [] [[PubMed]
  • 24. Fukahi K, Fukasawa M, Neufeld G, Itakura J, Korc M. Aberrant Expression of Neuropilin-1 and -2 in Human Pancreatic Cancer Cells. Clin Cancer Res (2004) 10(2):581–90. 10.1158/1078-0432.CCR-0930-03 [] [[PubMed]
  • 25. Dangle PP, Zaharieva B, Jia H, Pohar KS. Ras-MAPK Pathway as a Therapeutic Target in Cancer–Emphasis on Bladder Cancer. Recent Pat Anticancer Drug Discov (2009) 4(2):125–36. 10.2174/157489209788452812 [] [[PubMed]
  • 26. Ceccarelli S, Nodale C, Vescarelli E, Pontecorvi P, Manganelli V, Casella G, et al. . Neuropilin 1 Mediates Keratinocyte Growth Factor Signaling in Adipose-Derived Stem Cells: Potential Involvement in Adipogenesis. Stem Cells Int (2018) 2018:1075156. 10.1155/2018/1075156 ] [
  • 27. Antonelli AC, Binyamin A, Hohl TM, Glickman M S, Redelman-Sidi G. Bacterial Immunotherapy for Cancer Induces CD4-Dependent Tumor-Specific Immunity Through Tumor-Intrinsic Interferon-Gamma Signaling. Proc Natl Acad Sci U S A (2020) 117(31):18627–37. 10.1073/pnas.2004421117 ] [
  • 28. Meyerson M, Harlow E. Identification of G1 Kinase Activity for Cdk6, a Novel Cyclin D Partner. Mol Cell Biol (1994) 14(3):2077–86. 10.1128/mcb.14.3.2077 ] [
  • 29. Wang G, Zheng L, Yu Z, Liao G, Lu L, Xu R, et al. . Increased Cyclin-Dependent Kinase 6 Expression in Bladder Cancer. Oncol Lett (2012) 4(1):43–6. 10.3892/ol.2012.695 ] [
  • 30. Fogli S, Del Re M, Curigliano G, van Schaik RH, Lancellotti P, Danesi R. Drug-Drug Interactions in Breast Cancer Patients Treated With CDK4/6 Inhibitors. Cancer Treat Rev (2019) 74:21–8. 10.1016/j.ctrv.2019.01.006 [] [[PubMed]
  • 31. Sacaan AI, Thibault S, Hong M, Kondegowda NG, Nichols T, Li R, et al. . CDK4/6 Inhibition on Glucose and Pancreatic Beta Cell Homeostasis in Young and Aged Rats. Mol Cancer Res (2017) 15(11):1531–41. 10.1158/1541-7786.MCR-17-0172 [] [[PubMed]
  • 32. Li B, He H, Tao BB, Zhao ZY, Hu GH, Luo C, et al. . Knockdown of CDK6 Enhances Glioma Sensitivity to Chemotherapy. Oncol Rep (2012) 28(3):909–14. 10.3892/or.2012.1884 [] [[PubMed]
  • 33. Raleigh DR, Choksi PK, Krup AL, Mayer W, Santos N, Reiter JF. Hedgehog Signaling Drives Medulloblastoma Growth via CDK6. J Clin Invest (2018) 128(1):120–4. 10.1172/JCI92710 ] [
  • 34. Chang HR, Lian JD, Lo CW, Chang YC, Yang M Y, Wang CJ. Induction of Urothelial Proliferation in Rats by Aristolochic Acid Through Cell Cycle Progression Via Activation of Cyclin D1/Cdk4 and Cyclin E/Cdk2. Food Chem Toxicol (2006) 44(1):28–35. 10.1016/j.fct.2005.06.002 [] [[PubMed]
  • 35. Hwang JY, Sun Y, Carroll C R, Usherwood EJ. Neuropilin-1 Regulates the Secondary CD8 T Cell Response to Virus Infection. mSphere (2019) 4(3):e00221–19. 10.1128/mSphere.00221-19 ] [
  • 36. Kusunoki H, Tanaka T, Kohno T, Matsuhashi K, Hosoda K, Wakamatsu K, et al. . A Novel Neuropilin-1-Binding Sequence in the Human T-Cell Lymphotropic Virus Type 1 Envelope Glycoprotein. Biochim Biophys Acta Proteins Proteom (2018) 1866(4):541–8. 10.1016/j.bbapap.2018.02.003 [] [[PubMed]
  • 37. Abol-Enein H. Infection: Is it a Cause of Bladder Cancer? Scand J Urol Nephrol Suppl (2008) 218):79–84. 10.1016/s1473-3099(19)30402-5 [] [[PubMed]
  • 38. Chuang C K, Liao SK. Epstein-Barr Virus Infection in Urothelial Transitional Cell Carcinoma Tissues. BJU Int (2004) 93(4):495–8. 10.1111/j.1464-410x.2003.04687.x [] [[PubMed]
  • 39. Gaughan EM, Dezube BJ, Bower M, Aboulafia DM, Bohac G, Cooley TP, et al. . HIV-Associated Bladder Cancer: A Case Series Evaluating Difficulties in Diagnosis and Management. BMC Urol (2009) 9:10. 10.1186/1471-2490-9-10 ] [
  • 40. Korgaonkar SN, Feng X, Ross MD, Lu TC, D’Agati V, Iyengar R, et al. . HIV-1 Upregulates VEGF in Podocytes. J Am Soc Nephrol (2008) 19(5):877–83. 10.1681/ASN.2007050629 ] [
  • 41. Jia H, Lohr M, Jezequel S, Davis D, Shaikh S, Selwood D, et al. . Cysteine-Rich and Basic Domain HIV-1 Tat Peptides Inhibit Angiogenesis and Induce Endothelial Cell Apoptosis. Biochem Biophys Res Commun (2001) 283(2):469–79. 10.1006/bbrc.2001.4790 [] [[PubMed]
  • 42. Wang HB, Zhang H, Zhang JP, Li Y, Zhao B, Feng GK, et al. . Neuropilin 1 is an Entry Factor That Promotes EBV Infection of Nasopharyngeal Epithelial Cells. Nat Commun (2015) 6:6240. 10.1038/ncomms7240 ] [
  • 43. Gu YY, Luo B, Li CY, Huang LS, Chen G, Feng ZB, et al. . Expression and Clinical Significance of Neuropilin-1 in Epstein-Barr Virus-Associated Lymphomas. Cancer Biomark (2019) 25(3):259–73. 10.3233/CBM-192437 [] [[PubMed]
  • 44. West DC, Rees CG, Duchesne L, Patey SJ, Terry CJ, Turnbull JE, et al. . Interactions of Multiple Heparin Binding Growth Factors With Neuropilin-1 and Potentiation of the Activity of Fibroblast Growth Factor-2. J Biol Chem (2005) 280(14):13457–64. 10.1074/jbc.M410924200 [] [[PubMed]
  • 45. Sun HJ, Cai WW, Gong LL, Wang X, Zhu XX, Wan MY, et al. . FGF-2-Mediated FGFR1 Signaling in Human Microvascular Endothelial Cells is Activated by Vaccarin to Promote Angiogenesis. BioMed Pharmacother (2017) 95:144–52. 10.1016/j.biopha.2017.08.059 [] [[PubMed]
  • 46. Teng Y, Guo B, Mu X, Liu S. KIF26B Promotes Cell Proliferation and Migration Through the FGF2/ERK Signaling Pathway in Breast Cancer. BioMed Pharmacother (2018) 108:766–73. 10.1016/j.biopha.2018.09.036 [] [[PubMed]
  • 47. Li X, Gao Y, Li J, Zhang K, Han J, Li W, et al. . FOXP3 Inhibits Angiogenesis by Downregulating VEGF in Breast Cancer. Cell Death Dis (2018) 9(7):744. 10.1038/s41419-018-0790-8 ] [
  • 48. Campos-Mora M, Contreras-Kallens P, Galvez-Jiron F, Rojas M, Rojas C, Refisch A, et al. . CD4+Foxp3+T Regulatory Cells Promote Transplantation Tolerance by Modulating Effector CD4+ T Cells in a Neuropilin-1-Dependent Manner. Front Immunol (2019) 10:882. 10.3389/fimmu.2019.00882 ] [
  • 49. Takeuchi A, Eto M, Shiota M, Tatsugami K, Yokomizo A, Kuroiwa K, et al. . Sunitinib Enhances Antitumor Effects Against Chemotherapy-Resistant Bladder Cancer Through Suppression of ERK1/2 Phosphorylation. Int J Oncol (2012) 40(5):1691–6. 10.1159/000331881 [] [[PubMed]
  • 50. Grun D, Adhikary G, Eckert RL. NRP-1 Interacts With GIPC1 and SYX to Activate P38 MAPK Signaling and Cancer Stem Cell Survival. Mol Carcinog (2019) 58(4):488–99. 10.1002/mc.22943 ] [
  • 51. Nie L, Guo X, Esmailzadeh L, Zhang J, Asadi A, Collinge M, et al. . Transmembrane Protein ESDN Promotes Endothelial VEGF Signaling and Regulates Angiogenesis. J Clin Invest (2013) 123(12):5082–97. 10.1172/JCI67752 ] [
  • 52. Meissner M, Hrgovic I, Doll M, Kaufmann R. Ppardelta Agonists Suppress Angiogenesis in a VEGFR2-Dependent Manner. Arch Dermatol Res (2011) 303(1):41–7. 10.1007/s00403-010-1091-y [] [[PubMed]
  • 53. Mansour SMA, Ali SA, Nofal S, Soror SH. Targeting NUPR1 for Cancer Treatment: A Risky Endeavor. Curr Cancer Drug Targets (2020) 20(10):768–78. 10.2174/1568009620666200703152523 [] [[PubMed]
  • 54. Li A, Li X, Chen X, Zeng C, Wang Z, Li Z, et al. . NUPR1 Silencing Induces Autophagy-Mediated Apoptosis in Multiple Myeloma Cells Through the PI3K/AKT/Mtor Pathway. DNA Cell Biol (2020) 39(3):368–78. 10.1038/cddis.2016.175 [] [[PubMed]
  • 55. Noguchi S, Yamada N, Kumazaki M, Yasui Y, Iwasaki J, Naito S, et al. . Socs7, a Target Gene of Microrna-145, Regulates Interferon-Beta Induction Through STAT3 Nuclear Translocation in Bladder Cancer Cells. Cell Death Dis (2013) 4:e482. 10.1038/cddis.2013.11 ] [
  • 56. Rong ZH, Chang NB, Yao QP, Li T, Zhu XL, Cao Y, et al. . Suppression of Circdcbld1 Alleviates Intimal Hyperplasia in Rat Carotid Artery by Targeting Mir-145-3p/Neuropilin-1. Mol Ther Nucleic Acids (2019) 18:999–1008. 10.1016/j.omtn.2019.10.023 ] [
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.